Abstract
Endocannabinoid (eCB) function in the prefrontal cortex (PFC) presents as a highly connected, widespread hub for the modulation of a vast array of synaptic functions. Given the known role of the PFC in a range of disorders from mental retardation, neurodegenerative diseases, and schizophrenia to drug addiction, stress, and anxiety, all of which are characterized by aberrant function at the synaptic compartment (here termed “synaptopathies”), it follows that eCB dysfunction is implicated as a significant causal factor in a plethora of disease states. Genetic and environmental manipulation of the eCB system in the PFC has thus been extensively studied with regard to many of these diseases and highlighted significant causal factors in their development and expression. Here, we examine the current body of literature as well as extensions of theoretical implications regarding the role of eCBs in the generation and presenting characteristics of a range of disorders. Elucidating the functions of eCBs in disease states will participate to the understanding of their etiology and the development of innovative pharmacotherapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abush H, Akirav I (2013) Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory. Neuropsychopharmacology 38(8):1521–1534. doi:10.1038/npp.2013.51
Adamczyk P, Golda A, McCreary AC, Filip M, Przegaliński E (2008) Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 59(2):217–228
Aguiar DC, Terzian AL, Guimaraes FS, Moreira FA (2009) Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology 205(2):217–225. doi:10.1007/s00213-009-1532-5
Ahmed A, van der Marck MA, van den Elsen G, Olde Rikkert M (2015) Cannabinoids in late-onset Alzheimer’s disease. Clin Pharmacol Ther 97(6):597–606. doi:10.1002/cpt.117
Alen F, Moreno-Sanz G, Isabel de Tena A, Brooks RD, Lopez-Jimenez A, Navarro M, Lopez-Moreno JA (2008) Pharmacological activation of CB1 and D2 receptors in rats: predominant role of CB1 in the increase of alcohol relapse. Eur J Neurosci 27(12):3292–3298. doi:10.1111/j.1460-9568.2008.06302.x
Alváro-Bartolomé M, Garcià-Sevilla JA (2013) Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents. Neuroscience 247:294–308. doi:10.1016/j.neuroscience.2013.05.035
Anderson GR, Aoto J, Tabuchi K, Foldy C, Covy J, Yee AX, Wu D, Lee SJ, Chen L, Malenka RC, Sudhof TC (2015) beta-Neurexins control neural circuits by regulating synaptic endocannabinoid signaling. Cell 162(3):593–606. doi:10.1016/j.cell.2015.06.056
Andréasson S, Allebeck P, Engström A, Rydber U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2(8574):1483–1486
Argawal A, Neale MC, Prescott CA, Kendler KS (2004) A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 34(7):1227–1237
Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelot M, Soubrié P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132(1):104–106
Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117
Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol 5:37. doi:10.3389/fphar.2014.00037
Aso E, Ozaita A, Valdizan EM, Ledent C, Pazos A, Maldonado R, Valverde O (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105(2):565–572. doi:10.1111/j.1471-4159.2007.05149.x
Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2015) Cannabis-based medicine reduces multiple pathological processes in AbetaPP/PS1 mice. J Alzheimers Dis 43(3):977–991. doi:10.3233/JAD-141014
Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27(43):11700–11711. doi:10.1523/JNEUROSCI.1636-07.2007
Bari M, Battista N, Valenza M, Mastrangelo N, Malaponti M, Catanzaro G, Centonze D, Finazzi-Agro A, Cattaneo E, Maccarrone M (2013) In vitro and in vivo models of Huntington’s disease show alterations in the endocannabinoid system. FEBS J 280(14):3376–3388. doi:10.1111/febs.12329
Basavarajappa BS, Hungund BL (1999) Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Brain Res 815(1):89–97
Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano T, Gaetani S (2014) Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 40(3):701–712. doi:10.3233/JAD-131910
Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S (2015) The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 43(4):1115–1136. doi:10.3233/JAD-141635
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, Martin-Santos R, Hallak JE, Zuardi AW, Crippa JA (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36(6):1219–1226. doi:10.1038/npp.2011.6
Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, Chan K, Manners MT, Samad TA, Kennedy JD, Bingham B, Whiteside GT (2010) Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39(2):148–155. doi:10.1016/j.nbd.2010.03.020
Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK (2012) Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69(1):27–36. doi:10.1001/archgenpsychiatry.2011.161
Bird MK, Kirchhoff J, Djouma E, Lawrence AJ (2008) Metabotropic glutamate 5 receptors regulate sensitivity to ethanol in mice. Int J Neuropsychopharmacol 11(6):765–774. doi:10.1017/S1461145708008572
Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem Int 52(1-2):307–313. doi:10.1016/j.neuint.2007.06.031
Blanco E, Pavon FJ, Palomino A, Luque-Rojas MJ, Serrano A, Rivera P, Bilbao A, Alen F, Vida M, Suarez J, Rodriguez de Fonseca F (2015) Cocaine-induced behavioral sensitization is associated with changes in the expression of endocannabinoid and glutamatergic signaling systems in the mouse prefrontal cortex. Int J Neuropsychopharmacol 18(1). doi:10.1093/ijnp/pyu024
Blednov YA, Cravatt BF, Boehm SL 2nd, Walker D, Harris RA (2007) Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 32(7):1570–1582. doi:10.1038/sj.npp.1301274
Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62(10):1103–1110. doi:10.1016/j.biopsych.2006.12.001
Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM (2013) The endocannabinoid system and emotional processing: a pharmacological fMRI study with 9-tetrahydrocannabinol. Eur Neuropsychopharmacol 23(12):1687–1697. doi:10.1016/j.euroneuro.2013.06.009
Bowers ME, Ressler KJ (2015) An overview of translationally informed treatments for posttraumatic stress disorder: animal models of pavlovian fear conditioning to human clinical trials. Biol Psychiatry 78(5):E15–E27. doi:10.1016/j.biopsych.2015.06.008
Burgos H, Cofre C, Hernandez A, Saez-Briones P, Agurto R, Castillo A, Morales B, Zeise ML (2015) Methylphenidate has long-lasting metaplastic effects in the prefrontal cortex of adolescent rats. Behav Brain Res 291:112–117. doi:10.1016/j.bbr.2015.05.009
Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, Perez-Samartin A, Matute C, de la Torre R, Dierssen M, Maldonado R, Ozaita A (2013) Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 19(5):603–607. doi:10.1038/nm.3127
Bystrowska B, Smaga I, Frankowska M, Filip M (2014) Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. Prog Neuro-Psychopharmacol Biol Psychiatry 50:1–10. doi:10.1016/j.pnpbp.2013.12.002
Caballero A, Tseng KY (2012) Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia. Front Pharmacol 3:101. doi:10.3389/fphar.2012.00101
Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34(5):559–564. doi:10.1097/JCP.0000000000000180
Campos AC, Ferreira FR, da Silva WA Jr, Guimaraes FS (2013) Predator threat stress promotes long lasting anxiety-like behaviors and modulates synaptophysin and CB1 receptors expression in brain areas associated with PTSD symptoms. Neurosci Lett 533:34–38. doi:10.1016/j.neulet.2012.11.016
Carter E, Wang XJ (2007) Cannabinoid-mediated disinhibition and working memory: dynamical interplay of multiple feedback mechanisms in a continuous attractor model of prefrontal cortex. Cereb Cortex 17(Suppl 1):i16–i26. doi:10.1093/cercor/bhm103
Casadio P, Fernandes C, Murray RM, Di Forti M (2011) Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 35(8):1779–1787. doi:10.1016/j.neubiorev.2011.04.007
Castrén E, Elgersma Y, Maffei L, Hagerman R (2012) Treatment of neurodevelopmental disorders in adulthood. J Neurosci 32(41):14074–14079. doi:10.1523/JNEUROSCI.3287-12.2012
Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, Claes S, Van Laere K (2014) Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci 34(8):2822–2831. doi:10.1523/JNEUROSCI.0849-13.2014
Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K (2015) [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol 20(2):357–367. doi:10.1111/adb.12116
Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, Calabresi P (2005) Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington’s disease mice. Biol Psychiatry 57(12):1583–1589. doi:10.1016/j.biopsych.2005.03.008
Chakrabarti B, Persico A, Battista N, Maccarrone M (2015) Endocannabinoid signaling in autism. Neurotherapeutics 12(4):837–847. doi:10.1007/s13311-015-0371-9
Chakraborty R, Chatterjee A, Chaudhury S (2014) Impact of substance use disorder on presentation and short-term course of schizophrenia. Psychiatry J 2014:280243. doi:10.1155/2014/280243
Chen T, Lu JS, Song Q, Liu MG, Koga K, Descalzi G, Li YQ, Zhuo M (2014) Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome. Neuropsychopharmacology 39(8):1955–1967. doi:10.1038/npp.2014.44
Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis 42(4):1383–1396. doi:10.3233/JAD-140921
Chiu CQ, Puente N, Grandes P, Castillo PE (2010) Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 30(21):7236–7248. doi:10.1523/JNEUROSCI.0736-10.2010
Choi K, Le T, McGuire J, Xing G, Zhang L, Li H, Parker CC, Johnson LR, Ursano RJ (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res 46(7):882–889. doi:10.1016/j.jpsychires.2012.03.021
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370(9600):1706–1713. doi:10.1016/S0140-6736(07)61721-8
Cippitelli A, Astarita G, Duranti A, Caprioli G, Ubaldi M, Stopponi S, Kallupi M, Sagratini G, Rodriguez de Fonseca F, Piomelli D, Ciccocioppo R (2011) Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One 6(11):e28142. doi:10.1371/journal.pone.0028142
Colombo G, Orru A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MA (2007) The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 36(1):102–112. doi:10.1007/s12035-007-0017-y
Compton MT, Chien VH, Bollini AM (2009) Associations between past alcohol, cannabis, and cocaine use and current schizotypy among first-degree relatives of patients with schizophrenia and non-psychiatric controls. Psychiatry Q 80(3):143–154. doi:10.1007/s11126-009-9102-x
Contractor A, Klyachko VA, Portera-Cailliau C (2015) Altered neuronal and circuit excitability in fragile X syndrome. Neuron 87(4):699–715. doi:10.1016/j.neuron.2015.06.017
Cornish KM, Li L, Kogan CS, Jacquemont S, Turk J, Dalton A, Hagerman RJ, Hagerman PJ (2008) Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex 44(6):628–636. doi:10.1016/j.cortex.2006.11.002
Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, Barnes CC, Pierce K (2011) Neuron number and size in prefrontal cortex of children with autism. JAMA 306(18):2001–2010
Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P (2009) Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24(7):515–523. doi:10.1002/hup.1048
Dalton VS, Long LE, Weickert CS, Zavitsanou K (2011) Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36(8):1620–1630. doi:10.1038/npp.2011.43
Darnell JC, Klann E (2013) The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16(11):1530–1536. doi:10.1038/nn.3379
Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146(2):247–261
De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 19(2):5
Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103(1):9–15
den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S, Kruse CG, Maccarrone M, Wadman WJ, Werkman TR (2012) Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci USA 109(9):3534–3549
den Boon FS, Chameau P, Houthuijs K, Bolijn S, Mastrangelo N, Kruse CG, Maccarrone M, Wadman WJ, Werkman TR (2014) Endocannabinoids produced upon action potential firing evoke a Cl(-) current via type-2 cannabinoid receptors in the medial prefrontal cortex. Pflugers Arch 466(12):2257–2268. doi:10.1007/s00424-014-1502-6
Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, Ra S, Gray JM, Yang R, DeGruccio AM, Huang C, Cravatt BF, Glatt CE, Hill MN, Casey BJ, Lee FS (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 6:6395. doi:10.1038/ncomms7395
Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121(1–2):149–158
Domenici MR, Azad SC, Marsicano G, Shierloh A, Wotjak CT, Dodt HU, Zieglgänsberger W, Lutz B, Rammes G (2006) Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. j. Neuroscience 26(21):5794–5799
Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M (2009) Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington’s disease. Neuroscience 163(1):456–465. doi:10.1016/j.neuroscience.2009.06.014
Draycott B, Loureiro M, Ahmad T, Tan H, Zunder J, Laviolette SR (2014) Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. J Neurosci 34(39):13096–13109. doi:10.1523/JNEUROSCI.1297-14.2014
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57(6):594–608. doi:10.1016/j.biopsych.2004.12.006
Egertová M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422(2):159–171
Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119(2):481–496. doi:10.1016/s0306-4522(03)00145-3
Eggan SM, Lewis DA (2007) Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17(1):175–191. doi:10.1093/cercor/bhj136
Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65(7):772–784. doi:10.1001/archpsyc.65.7.772
Eggan SM, Mizoguchi Y, Stoyak SR, Lewis DA (2010) Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex 20(5):1164–1174. doi:10.1093/cercor/bhp179
Eisenhardt M, Leixner S, Spanagel R, Bilbao A (2015) Quantification of alcohol drinking patterns in mice. Addict Biol. doi:10.1111/adb.12325
Elbatsh MM, Moklas MA, Marsden CA, Kendall DA (2012) Antidepressant-like effects of Delta(9)-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression. Pharmacol Biochem Behav 102(2):357–365. doi:10.1016/j.pbb.2012.05.009
Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL (2008) Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 18(11):826–834. doi:10.1016/j.euroneuro.2008.06.009
Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernandez-Ruiz J, Alexander SP, Callado LF (2015) The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addict Biol 20(4):773–783. doi:10.1111/adb.12160
Fagan SG, Campbell VA (2014) The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 171(6). doi:10.1111/bph.2014.171.issue-6
Farkas S, Nagy K, Palkovits M, Kovacs GG, Jia Z, Donohue S, Pike V, Halldin C, Mathe D, Harkany T, Gulyas B, Csiba L (2012) [(1)(2)(5)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease. Neurochem Int 60(3):286–291. doi:10.1016/j.neuint.2011.11.004
Fergusson DM, Horwood LJ (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95(4):502–520
Foldy C, Malenka RC, Sudhof TC (2013) Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 78(3):498–509. doi:10.1016/j.neuron.2013.02.036
Fortin DA, Levine ES (2007) Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex 17(1):163–174. doi:10.1093/cercor/bhj133
Foti DJ, Kotov R, Guey LT, Bromet EJ (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167(8):987–993. doi:10.1176/appi.ajp.2010.09020189
Fourgeaud L, Mato S, Bouchet D, Hemar A, Worley PF, Manzoni OJ (2004) A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. J Neurosci 24(31):6939–6945. doi:10.1523/JNEUROSCI.0671-04.2004
Fowler CJ (2015) The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs – a practical view. Eur Neuropsychopharmacol 25(6):749–762. doi:10.1016/j.euroneuro.2015.02.005
Fraser GA (2009) The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15(1):84–88. doi:10.1111/j.1755-5949.2008.00071.x
Freedland CS, Sharpe AL, Samson HH, Porrino LJ (2001) Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 25(2):277–282
Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O’Carroll C, Atakan Z, Zuardi AW, McGuire PK (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66(1):95–105. doi:10.1001/archgenpsychiatry.2008.519
Gallate JE, Saharov T, Mallet PE, McGregor IS (1999) Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 370(3):233–240
Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, Gasparini F, Oostra BA, D'Hooge R, Willemsen R (2013) Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 239:72–79. doi:10.1016/j.bbr.2012.10.059
Garber KB, Visootsak J, Warren ST (2008) Fragile X syndrome. Eur J Hum Genet 16(6):666–672. doi:10.1038/ejhg.2008.61
Garner GC, Wetmore DZ (2012) Synaptic pathology of down syndrome. Adv Exp Med Biol 970:451–468
George O, Koob GF (2010) Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev 35(2):232–247. doi:10.1016/j.neubiorev.2010.05.002
Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29(11):2108–2114. doi:10.1038/sj.npp.1300558
Glass M (2001) The role of cannabinoids in neurodegenerative diseases. Prog Neuro-Psychopharmacol Biol Psychiatry 25(4):743–765
Glass M, Faull RL, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience 56(3):523–527
Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97(3):505–519
Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102(51):18620–18625. doi:10.1073/pnas.0509591102
Goldman-Rakic PS (1990) Cellular and circuit basis of working memory in prefrontal cortex of nonhuman primates. Prog Brain Res 85:325–335
Goldstein RZ, Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12(11):652–669. doi:10.1038/nrn3119
Gomes FV, Issy AC, Ferreira FR, Viveros MP, Del Bel EA, Guimaraes FS (2015a) Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol 18(5). doi:10.1093/ijnp/pyu041
Gomes FV, Llorente R, Del Bel EA, Viveros MP, Lopez-Gallardo M, Guimaraes FS (2015b) Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res 164(1-3):155–163. doi:10.1016/j.schres.2015.01.015
Gorzalka BB, Hill MN (2011) Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 35(7):1575–1585. doi:10.1016/j.pnpbp.2010.11.021
Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry 67(3):199–207. doi:10.1016/j.biopsych.2009.08.026
Grant SG (2003) Synapse signalling complexes and networks: machines underlying cognition. Bioessays 25(12):1229–1235. doi:10.1002/bies.10381
Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57(3):261–267. doi:10.1016/j.biopsych.2004.10.032
Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, Makriyannis A, Poulton R, Patel S, Hariri AR, Caspi A, Moffitt TE, Kunos G, Holmes A (2013) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18(7):813–823. doi:10.1038/mp.2012.72
Gururajan A, Taylor DA, Malone DT (2011) Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav Brain Res 222(2):299–308. doi:10.1016/j.bbr.2011.03.053
Hadland SE, Knight JR, Harris SK (2015) The knowledge gaps for medical marijuana in pediatric conditions. J Dev Behav Pediatr 36(9):767–768
Hajós M, Hoffmann WE, Kocsis B (2008) Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63(11):1075–1083. doi:10.1016/j.biopsych.2007.12.005
Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16(7):1395–1398. doi:10.1046/j.1460-9568.2002.02192.x
Haller J, Szirmai M, Varga B, Ledent C, Freund TF (2005) Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 16(5-6):415–422
Hambrecht M, Häfner H (2000) Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 34(3):468–475
Hansson AC, Bermudez-Silva FJ, Malinen H, Hyytia P, Sanchez-Vera I, Rimondini R, Rodriguez de Fonseca F, Kunos G, Sommer WH, Heilig M (2007) Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32(1):117–126. doi:10.1038/sj.npp.1301034
Hayase T (2011) Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol 11:6. doi:10.1186/1471-2210-11-6
Hayashi Y, Momiyama A, Takahashi H, Ohishi J, Ogawa-Meguro R, Shigemoto R, Mizuno N, Nakanishi S (1993) Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb. Nature 366(6456):687–690
Heng L, Beverley JA, Steiner H, Tseng KY (2011) Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 65(4):278–286. doi:10.1002/syn.20844
Herkenham M (1992) Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 654:19–32
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87(5):1932–1936
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563–583
Higuera-Matas A, Soto-Montenegro ML, del Olmo N, Miguens M, Torres I, Vaquero JJ, Sanchez J, Garcia-Lecumberri C, Desco M, Ambrosio E (2008) Augmented acquisition of cocaine self-administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid agonist during adolescence. Neuropsychopharmacology 33(4):806–813. doi:10.1038/sj.npp.1301467
Hill MN, Gorzalka BB (2005) Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 15(6):593–599. doi:10.1016/j.euroneuro.2005.03.003
Hill MN, Gorzalka BB (2009) Impairments in endocannabinoid signaling and depressive illness. JAMA 301(11):1165–1166. doi:10.1001/jama.2009.369
Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB (2006) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31(12):2591–2599. doi:10.1038/sj.npp.1301092
Hill MN, Barr AM, Ho WS, Carrier EJ, Gorzalka BB, Hillard CJ (2007) Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J Neurochem 103(1):47–56. doi:10.1111/j.1471-4159.2007.04688.x
Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008a) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106(6):2322–2336. doi:10.1111/j.1471-4159.2008.05567.x
Hill MN, Ho WS, Hillard CJ, Gorzalka BB (2008b) Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm (Vienna) 115(12):1673–1679. doi:10.1007/s00702-008-0131-7
Hill MN, Hillard CJ, McEwen BS (2011a) Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress. Cereb Cortex 21(9):2056–2064. doi:10.1093/cercor/bhq280
Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, Liu QS, Gorzalka BB, Hillard CJ (2011b) Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31(29):10506–10515. doi:10.1523/JNEUROSCI.0496-11.2011
Hillard CJ, Liu QS (2014) Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des 20(23):39
Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, Morse C, Zoghbi SS, Pike VW, Innis RB, Heilig M (2013) Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry 18(8):916–921. doi:10.1038/mp.2012.100
Ho WS, Barrett DA, Randall MD (2008) ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155(6):837–846. doi:10.1038/bjp.2008.324
Hojo S, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikaway K, Uezono Y (2008) mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108(3):308–319
Hu B, Doods H, Treede RD, Ceci A (2009) Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 143(3):206–212. doi:10.1016/j.pain.2009.02.018
Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, Mann JJ, Arango V (2004) Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9(2):184–190. doi:10.1038/sj.mp.4001376
Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D (2014) Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 76(Pt B):416–424. doi:10.1016/j.neuropharm.2013.07.028
Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J, Horton WJ, Filbey F (2008) The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 65(7):841–850. doi:10.1001/archpsyc.65.7.841
Imperatore R, Morello G, Luongo L, Taschler U, Romano R, De Gregorio D, Belardo C, Maione S, Di Marzo V, Cristino L (2015) Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB1 R signaling and anxiety-like behavior. J Neurochem 135(4):799–813. doi:10.1111/jnc.13267
Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162(1-3):153–161. doi:10.1016/j.schres.2015.01.033
Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, Arinami T (2010) Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67(10):974–982. doi:10.1016/j.biopsych.2009.09.024
Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, Deep-Soboslay A, Innis RB, Kleinman JE (2012) Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res 141(2–3):185–188. doi:10.1016/j.schres.2012.07.021
Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 3:1080. doi:10.1038/ncomms2045
Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162(8):1403–1413
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380. doi:10.1152/physrev.00019.2008
Kasanetz F, Lafourcade M, Deroche-Gamonet V, Revest JM, Berson N, Balado E, Fiancette JF, Renault P, Piazza PV, Manzoni OJ (2013) Prefrontal synaptic markers of cocaine addiction-like behavior in rats. Mol Psychiatry 18(6):729–737. doi:10.1038/mp.2012.59
Kasckow JW, Mulchahey JJ, Geracioti TD Jr (2004) Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuro-Psychopharmacol Biol Psychiatry 28(2):291–295. doi:10.1016/j.pnpbp.2003.10.007
Katona I, Freund TF (2012) Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35:529–558. doi:10.1146/annurev-neuro-062111-150420
Kerr DM, Downey L, Conboy M, Finn DP, Roche M (2013) Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 249:124–132. doi:10.1016/j.bbr.2013.04.043
Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313–327. doi:10.1002/mds.26142
Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. Synapse 25(3):306–308
Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Weis S (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm (Vienna) 114(8):1055–1063. doi:10.1007/s00702-007-0660-5
Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkotter J, Piomelli D, Leweke FM (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194(4):371–372. doi:10.1192/bjp.bp.108.053843
Kramvis I, Mansvelder HD, Loos M, Meredith R (2013) Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model. Front Behav Neurosci 7:172. doi:10.3389/fnbeh.2013.00172
Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411–429. doi:10.1146/annurev-med-061109-134644
Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ (2007) Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2(8):e709. doi:10.1371/journal.pone.0000709
Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, De Smedt-Peyrusse V, Labrousse VF, Bretillon L, Matute C, Rodriguez-Puertas R, Laye S, Manzoni OJ (2011) Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 14(3):345–350. doi:10.1038/nn.2736
Larrieu T, Madore C, Joffre C, Layé S (2012) Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice. J Physiol Biochem 68(4):671–681
Lastres-Becker I, Fezza F, Cabeira M, Bisogno T, Ramos JA, Milone A, Fernàndez-Ruiz J, Di Marzo V (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease. Neuroreport 12(10):2125–2129
Lastres-Becker I, Gomez M, De Miguel R, Ramos JA, Fernandez-Ruiz J (2002) Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease. Neurotox Res 4(7-8):601–608. doi:10.1080/10298420290030514
Lee TT, Hill MN (2013) Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB(1) receptor binding in male rats. Neuroscience 249:106–114. doi:10.1016/j.neuroscience.2012.11.017
Lee SH, Ledri M, Toth B, Marchionni I, Henstridge CM, Dudok B, Kenesei K, Barna L, Szabo SI, Renkecz T, Oberoi M, Watanabe M, Limoli CL, Horvai G, Soltesz I, Katona I (2015) Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. J Neurosci 35(27):10039–10057. doi:10.1523/JNEUROSCI.4112-14.2015
Lehtonen M, Storvik M, Tupala E, Hyytia P, Tiihonen J, Callaway JC (2010) Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics. Eur Neuropsychopharmacol 20(4):245–252. doi:10.1016/j.euroneuro.2009.12.008
Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105(8):749–752
Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665–1669
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. doi:10.1038/tp.2012.15
Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28(2):325–334
Lin HC, Mao SC, Su CL, Gean PW (2009) The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 19(1):165–175. doi:10.1093/cercor/bhn075
Linzen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51(4):273–279
Lisboa SF, Borges AA, Nejo P, Fassini A, Guimaraes FS, Resstel LB (2015) Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: additional evidence. Prog Neuro-Psychopharmacol Biol Psychiatry 59:76–83. doi:10.1016/j.pnpbp.2015.01.005
Liu ZH, Smith CB (2009) Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett 454(1):62–66. doi:10.1016/j.neulet.2009.02.066
Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31(4):795–803. doi:10.1038/sj.npp.1300838
Long LE, Lind J, Webster M, Weickert CS (2012) Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci 13(87):1–14
Lovelace JW, Vieira PA, Corches A, Mackie K, Korzus E (2014) Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity. Neuropsychopharmacology 39(7):1685–1693. doi:10.1038/npp.2014.15
Lovelace JW, Corches A, Vieira PA, Hiroto AS, Mackie K, Korzus E (2015) An animal model of female adolescent cannabinoid exposure elicits a long-lasting deficit in presynaptic long-term plasticity. Neuropharmacology 99:242–255. doi:10.1016/j.neuropharm.2015.04.034
Lu AT, Ogdie MN, Järvelin MR, Moilanen IK, Loo SK, McCracken JT, McGough JJ, Yang MH, Peltonen L, Nelson SF, Cantor RM, Smalley SL (2008) Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 147B(8):1488–1494. doi:10.1002/ajmg.b
Luongo FJ, Horn ME, Sohal VS (2015) Putative microcircuit-level substrates for attention are disrupted in mouse models of autism. Biol Psychiatry. doi:10.1016/j.biopsych.2015.04.014
Lüscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69(4):650–663. doi:10.1016/j.neuron.2011.01.017
Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG (2003) Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 289(4):427–433
Lysenko LV, Kim J, Henry C, Tyrtyshnaia A, Kohnz RA, Madamba F, Simon GM, Kleschevnikova NE, Nomura DK, Ezekowitz RA, Kleschevnikov AM (2014) Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome. PLoS One 9(12):e114521. doi:10.1371/journal.pone.0114521
Maccarrone M, Valverde O, Barbaccia ML, Castañé A, Maldonado R, Ledent C, Parmentier M, Finazzi-Agrò A (2002) Age-related changes of anandamide metabolism in CB1 receptor knockout mice: correlation with behaviour. Eur J Neurosci 15(7):1178–1186
Maccarrone M, Battista N, Centonze D (2007) The endocannabinoid pathway in Huntington’s disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 81(5-6):349–379. doi:10.1016/j.pneurobio.2006.11.006
Maccioni P, Colombo G, Carai MA (2010) Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. CNS Neurol Disord Drug Targets 9(1):55–59
Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95(2):153–164
Manna SS, Umathe SN (2012) A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine. Eur J Pharmacol 685(1-3):81–90. doi:10.1016/j.ejphar.2012.04.023
Manuel I, Gonzalez de San Roman E, Giralt MT, Ferrer I, Rodriguez-Puertas R (2014) Type-1 cannabinoid receptor activity during Alzheimer’s disease progression. J Alzheimers Dis 42(3):761–766. doi:10.3233/JAD-140492
Mao SC, Chang CH, Wu CC, Orejarena MJ, Manzoni OJ, Gean PW (2013) Inhibition of spontaneous recovery of fear by mGluR5 after prolonged extinction training. PLoS One 8(3):e59580. doi:10.1371/journal.pone.0059580
Marinho EA, Oliveira-Lima AJ, Santos R, Hollais AW, Baldaia MA, Wuo-Silva R, Yokoyama TS, Takatsu-Coleman AL, Patti CL, Longo BM, Berro LF, Frussa-Filho R (2015) Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 58:22–31. doi:10.1016/j.pnpbp.2014.11.010
Maroof N, Ravipati S, Pardon MC, Barrett DA, Kendall DA (2014) Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AbetaPPswe/PS1DeltaE9 mouse model of Alzheimer’s disease. J Alzheimers Dis 42(1):227–245. doi:10.3233/JAD-131961
Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, Li W, Xu C, Moller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13(8):951–957. doi:10.1038/nn.2601
Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11(12):4213–4225
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls excitation of aversive memories. Nature 418(6897):530–534
Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159(4):379–387. doi:10.1007/s00213-001-0946-5
Martin HG, Bernabeu A, Lassalle O, Bouille C, Beurrier C, Pelissier-Alicot AL, Manzoni OJ (2015) Endocannabinoids mediate muscarinic acetylcholine receptor-dependent long-term depression in the adult medial prefrontal cortex. Front Cell Neurosci 9(457):1–11. doi:10.3389/fncel.2015.00457
Mato S, Pazos A (2004) Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46(5):716–726. doi:10.1016/j.neuropharm.2003.11.004
Mato S, Aso E, Castro E, Martin M, Valverde O, Maldonado R, Pazos A (2007) CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 103(5):2111–2120. doi:10.1111/j.1471-4159.2007.04961.x
Mato S, Vidal R, Castro E, Diaz A, Pazos A, Valdizan EM (2010) Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 77(3):424–434. doi:10.1124/mol.109.060079
McEwan BS, Bowles NP, Gray JD, Hill MN, Hunter RG, Karatsoreos IN, Nasca C (2015) Mechanisms of stress in the brain. Nat Neurosci 18(10):135301363. doi:10.1038/nn.4086
McLaughlin RJ, Gobbi G (2012) Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 204:134–144. doi:10.1016/j.neuroscience.2011.07.052
McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ, Gorzalka BB (2012) Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol 22(9):664–671. doi:10.1016/j.euroneuro.2012.01.004
McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ, Gorzalka BB (2013) Upregulation of CB(1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 237:333–337. doi:10.1016/j.bbr.2012.09.053
McLaughlin RJ, Hill MN, Gorzalka BB (2014) A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neurosci Biobehav Rev 42:116–131. doi:10.1016/j.neubiorev.2014.02.006
McReynolds JR, Doncheck EM, Vranjkovic O, Ganzman GS, Baker DA, Hillard CJ, Mantsch JR (2015) CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats. Psychopharmacology. doi:10.1007/s00213-015-4092-x
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007) Cannabidiol – recent advances. Chem Biodivers 4(8):1678–1692
Melis M, Pistis M (2012) Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond Ser B Biol Sci 367(1607):3276–3285. doi:10.1098/rstb.2011.0383
Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74(1):49–56. doi:10.1016/j.neuron.2012.03.009
Miller P, Lawrie SM, Hodges A, Clafferty RA, Cunningham Owens DG, Johnstone EC (2001) Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Br J Psychiatry 178(524–530):524
Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long JZ, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51(4):455–466
Mullard A (2015) Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov 14(3):151–153. doi:10.1038/nrd4555
Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 192(1):61–70. doi:10.1007/s00213-006-0689-4
Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, Sindelar DK, Nomikos GG (2006) The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology 184(1):26–35. doi:10.1007/s00213-005-0234-x
Negrete JC (1989) Cannabis and schizophrenia. Br J Addict 84(4):349–351
Negrete JC, Knapp WP (1986) The effects of cannabis use on the clinical condition of schizophrenics. NIDA Res Monogr 67:321–327
Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172(4):556–560. doi:10.1007/s00221-006-0503-x
Ninan I (2011) Oxytocin suppresses basal glutamatergic transmission but facilitates activity-dependent synaptic potentiation in the medial prefrontal cortex. J Neurochem 119(2):324–331. doi:10.1111/j.1471-4159.2011.07430.x
Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Deprés JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM, investigators S (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (13):1547-1560. doi:10.1001/jama.299.13.1547
Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Hope B, Lujilde J, Inada T, Iwasaki S, Macharia D, Teasenfitz L, Arinami T, Uhl GR (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3(2):e1640. doi:10.1371/journal.pone.0001640
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3(3):167–175. doi:10.1016/j.cmet.2006.02.004
Pardini M, Krueger F, Koenigs M, Raymont V, Hodgkinson C, Zoubak S, Goldman D, Grafman J (2012) Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury. Transl Psychiatry 2:e75. doi:10.1038/tp.2012.1
Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH (2012) Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 4(7-8):649–659. doi:10.1002/dta.1377
Patel S, Roelke CT, Rademacher DJ, Hillard CJ (2005) Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 21(4):1057–1069. doi:10.1111/j.1460-9568.2005.03916.x
Pava MJ, Woodward JJ (2014) Chronic ethanol alters network activity and endocannabinoid signaling in the prefrontal cortex. Front Integr Neurosci 8(58):1–12. doi:10.3389/fnint.2014.00058
Penagarikano O, Mulle JG, Warren ST (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8:109–129. doi:10.1146/annurev.genom.8.080706.092249
Perry EK, Lee ML, Martin-Ruiz CM, Court JA, Voisen SG, Merrit J, Folly E, Iversen PE, Bauman ML, Perry RH, Wenk GL (2001) Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 158(7):1058–1066
Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ (2008) Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54(1):108–116. doi:10.1016/j.neuropharm.2007.06.012
Raver SM, Haughwout SP, Keller A (2013) Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology 38(12):2338–2347. doi:10.1038/npp.2013.164
Realini N, Viganò D, Guidali C, Zamberletti E, Rubino T, Parolaro D (2011) Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 60(2-3):235–243. doi:10.1016/j.neuropharm.2010.09.003
Rey AA, Purrio M, Viveros MP, Lutz B (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37(12):2624–2634. doi:10.1038/npp.2012.123
Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36(4):577–584
Rinaldi T, Perrodin C, Markram H (2008) Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic Acid animal model of autism. Front Neural Circuits 2:4. doi:10.3389/neuro.04.004.2008
Rios C, Gomes I, Devi LA (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148(4):387–395. doi:10.1038/sj.bjp.0706757
Rive MM, van Rooijen G, Veltman DJ, Phillips ML, Schene AH, Ruhe HG (2013) Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. Neurosci Biobehav Rev 37(10 Pt 2):2529–2553. doi:10.1016/j.neubiorev.2013.07.018
Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21(3):823–833
Rodriguez-Gaztelumendi A, Rojo ML, Pazos A, Diaz A (2009) Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 108(6):1423–1433. doi:10.1111/j.1471-4159.2009.05898.x
Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A (2014) Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 34(8):587–591. doi:10.1007/s40261-014-0212-3
Roullet FI, Lai JK, Foster JA (2013) In utero exposure to valproic acid and autism – a current review of clinical and animal studies. Neurotoxicol Teratol 36:47–56. doi:10.1016/j.ntt.2013.01.004
Rubino T, Parolaro D (2008) Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286(1–2 Suppl 1):S108–S113. doi:10.1016/j.mce.2008.02.003
Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, Parolaro D (2008a) CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54(1):151–160. doi:10.1016/j.neuropharm.2007.06.024
Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D (2008b) Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18(6):1292–1301. doi:10.1093/cercor/bhm161
Rubino T, Viganò D, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, Cherubino F, Romualdi P, Candeletti S, Sala M, Parolaro D (2008c) Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33(11):2760–2771. doi:10.1038/sj.npp.1301664
Rubino T, Realini N, Braida D, Alberio T, Capurro V, Viganò D, Guidali C, Sala M, Fasano M, Parolaro D (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15(4):291–302. doi:10.1007/s12640-009-9031-3
Rubino T, Zamberletti E, Parolaro D (2015) Endocannabinoids and Mental Disorders. Handb Exp Pharmacol 231:261–283. doi:10.1007/978-3-319-20825-1_9
Rutkowska M, Jachimczuk O (2004) Antidepressant--like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 61(2):165–167
Saito A, Ballinger MD, Pletnikov MV, Wong DF, Kamiya A (2013) Endocannabinoid system: potential novel targets for treatment of schizophrenia. Neurobiol Dis 53:10–17. doi:10.1016/j.nbd.2012.11.020
Salio C, Fischer J, Franzoi MF, Mackie K, Kaneko T, Conrath M (2001) CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 12(17):3689–3692
Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 176(2):223–232. doi:10.1007/s00213-004-1877-8
Schmöle AC, Lundt R, Ternes S, Albayram O, Ulas T, Schultze JL, Bano D, Nicotera P, Alferink J, Zimmer A (2015) Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer’s disease mouse model. Neurobiol Aging 36(2):710–719. doi:10.1016/j.neurobiolaging.2014.09.019
Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28(10):1760–1769. doi:10.1038/sj.npp.1300225
Seamans JK, Floresco SB, Phillips AG (1995) Functional differences between the prelimbic and anterior cingulate regions of the rat prefrontal cortex. Behav Neurosci 109(6):1063–1073
Seillier A, Martinez AA, Giuffrida A (2013) Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB(1) receptors: implications for schizophrenia. Neuropsychopharmacology 38(9):1816–1824. doi:10.1038/npp.2013.81
Serra G, Fratta W (2007) A possible for for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health 3(25):11. doi:10.1186/1745-0179-3-
Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14(8):573–582. doi:10.1097/01.fbp.0000104880.69384.38
Sheinin A, Talani G, Davis MI, Lovinger DM (2008) Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region. J Neurophysiol 100(2):1041–1052. doi:10.1152/jn.90226.2008
Sidorov MS, Krueger DD, Taylor M, Gisin E, Osterweil EK, Bear MF (2014) Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice. Genes Brain Behav 13(5):451–458. doi:10.1111/gbb.12137
Smaga I, Bystrowska B, Gawlinski D, Pomierny B, Stankowicz P, Filip M (2014) Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotox Res 26(2):190–206. doi:10.1007/s12640-014-9465-0
Solas M, Francis PT, Franco R, Ramirez MJ (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging 34(3):805–808. doi:10.1016/j.neurobiolaging.2012.06.005
Song J, Singh M (2013) From hub proteins to hub modules: the relationship between essentiality and centrality in the yeast interactome at different scales of organization. PLoS Comput Biol 9(2):e1002910. doi:10.1371/journal.pcbi.1002910
Speed HE, Masiulis I, Gibson JR, Powell CM (2015) Increased cortical inhibition in autism-linked neuroligin-3R451C mice is due in part to loss of endocannabinoid signaling. PLoS One 10(10):1–16
Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW (2003) Abnormal neural synchrony in schizophrenia. J Neurosci 23(19):7407–7411
Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bachli H, Holsboer F, Lutz B, Wotjak CT (2008) Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 8(3):196–208. doi:10.1038/sj.tpj.6500466
Tan H, Ahmad T, Loureiro M, Zunder J, Laviolette SR (2014) The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Front Psychiatry 5:73. doi:10.3389/fpsyt.2014.00073
Tang AH, Alger BE (2015) Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci 35(9):3938–3945. doi:10.1523/JNEUROSCI.4499-14.2015
Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedj F, Janel N, Chavis P, Delabar J, Manzoni OJ (2014) Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. J Neurosci 34(4):1138–1147. doi:10.1523/JNEUROSCI.2852-13.2014
Thorat SN, Bhargava HN (1994) Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260(1):5–13
Thornberg SA, Saklad SR (1996) A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16(1):82–93
Treffert DA (1978) Marijuana use in schizophrenia: a clear hazard. Am J Psychiatry 135(10):1213–1215
Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165–179
Turner WM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16(1):87–95
Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138(4):544–553. doi:10.1038/sj.bjp.0705100
Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11(2):100–113. doi:10.1038/nrn2774
Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96(4):376–381
Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7(5). doi:10.1038/sj.mp.4001029
Umathe SN, Manna SS, Jain NS (2011) Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav Brain Res 223(1):125–134. doi:10.1016/j.bbr.2011.04.031
Urigüen L, Fernández B, Romero EM, De Pedro N, Delgado MJ, Guaza C, Schmidhammer H, Viveros MP (2002) Effects of 14-methoxymetopon, a potent opioid agonist, on the responses to the tail electric stimulation test and plus-maze activity in male rats: neuroendocrine correlates. Brain Res Bull 57(5):661–666
Uylings HBM, Groenewegen HJ, Kolb B (2003) Do rats have a prefrontal cortex? Behav Brain Res 146(1-2):3–17. doi:10.1016/j.bbr.2003.09.028
Valverde O, Torrens M (2012) CB1 receptor-deficient mice as a model for depression. Neuroscience 204:193–206. doi:10.1016/j.neuroscience.2011.09.031
Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, Vandenberghe W (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51(9):1413–1417. doi:10.2967/jnumed.110.077156
Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE (2013) Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem 56(11):4537–4550. doi:10.1021/jm400268b
Viganò D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T (2004) Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci 20(7):1849–1857. doi:10.1111/j.1460-9568.2004.3645.x
Viganò D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, Parolaro D (2005) Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology 182(4):527–536. doi:10.1007/s00213-005-0114-4
Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di Marzo V, Parolaro D (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12(5):599–614. doi:10.1017/S1461145708009371
Vinod KY, Hungund BL (2006) Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci 27(10):539–545. doi:10.1016/j.tips.2006.08.006
Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, Hungund BL (2005) Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 57(5):480–486. doi:10.1016/j.biopsych.2004.11.033
Vinod KY, Yalamanchili R, Xie S, Cooper TB, Hungund BL (2006) Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem Int 49(6):619–625. doi:10.1016/j.neuint.2006.05.002
Vinod KY, Sanguino E, Yalamanchili R, Manzanares J, Hungund BL (2008) Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J Neurochem 104(1):233–243. doi:10.1111/j.1471-4159.2007.04956.x
Volk DW, Lewis DA (2015) The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. Biol Psychiatry. doi:10.1016/j.biopsych.2015.06.015
Volk DW, Eggan SM, Lewis DA (2010) Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 167(12):1489–1498. doi:10.1176/appi.ajp.2010.10030318
Volk DW, Siegel BI, Verrico CD, Lewis DA (2013) Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophr Res 147(1):53–57. doi:10.1016/j.schres.2013.02.038
Watanabe S, Doshi M, Hamazaki T (2003) n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69(1):51–59
Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, Gall CM, Piomelli D (2015) Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci USA 112(45):14084–14089
Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52(2):90–110. doi:10.1159/000087097
Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, Reilly SK, Lin L, Fertuzinhos S, Miller JA, Murtha MT, Bichsel C, Niu W, Cotney J, Ercan-Sencicek AG, Gockley J, Gupta AR, Han W, He X, Hoffman EJ, Klei L, Lei J, Liu W, Liu L, Lu C, Xu X, Zhu Y, Mane SM, Lein ES, Wei L, Noonan JP, Roeder K, Devlin B, Sestan N, State MW (2013) Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 155(5):997–1007. doi:10.1016/j.cell.2013.10.020
Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG (2005) A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26(12):609–617. doi:10.1016/j.tips.2005.10.006
Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, Ye W, Dannals RF, Ravert HT, Nandi A, Rahmim A, Ming JE, Grachev I, Roy C, Cascella N (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage 52(4):1505–1513. doi:10.1016/j.neuroimage.2010.04.034
Wyrofsky R, McGonigle P, Van Bockstaele EJ (2015) Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease. Expert Opin Drug Discovery 10(1):17–36. doi:10.1517/17460441.2014.966680
Xu ZH, Yang Q, Feng B, Liu SB, Zhang N, Xing JH, Li XQ, Wu YM, Gao GD, Zhao MG (2012) Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener 7(24):1–14
Yamaguchi K, Kandel DB (1984) Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health 74(7):673–681
Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, Blat Y, Westphal RS, Zaczek R, Lewis DA, Gonzalez-Burgos G (2011) Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J Physiol 589(Pt 20):4857–4884. doi:10.1113/jphysiol.2011.212225
You IJ, Jung YH, Kim MJ, Kwon SH, Hong SI, Lee SY, Jang CG (2012) Alterations in the emotional and memory behavioral phenotypes of transient receptor potential vanilloid type 1-deficient mice are mediated by changes in expression of 5-HT(1)A, GABA(A), and NMDA receptors. Neuropharmacology 62(2):1034–1043. doi:10.1016/j.neuropharm.2011.10.013
Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 28(2):355–360. doi:10.1016/j.pnpbp.2003.11.005
Zhang L, Alger BE (2010) Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 30(16):5724–5729. doi:10.1523/JNEUROSCI.0795-10.2010
Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B (2011) Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36(4):805–818. doi:10.1038/npp.2010.214
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56(10):485–486
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA (2006) Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20(5):683–686
Acknowledgments
This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), a NIDA/INSERM fellowship to AFS and grants from Agence Nationale de la Recherche (CYFIP-Aut to HSM and OM), the FRAXA Research Foundation; and the Fondation Jêrome Lejeune (to HSM and OM). The authors thank Laura F. Scheyer for the design and execution of the chapter’s schematic diagram.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Scheyer, A.F., Martin, H.G.S., Manzoni, O.J. (2017). The Endocannabinoid System in Prefrontal Synaptopathies. In: Melis, M. (eds) Endocannabinoids and Lipid Mediators in Brain Functions. Springer, Cham. https://doi.org/10.1007/978-3-319-57371-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-57371-7_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-57369-4
Online ISBN: 978-3-319-57371-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)